<DOC>
	<DOCNO>NCT01129310</DOCNO>
	<brief_summary>The investigator hypothesize IXO chemotherapy improvement response rate acceptable toxicity uncurable metastatic gastric cancer compare historical control .</brief_summary>
	<brief_title>First Line Study Irinotecan , Capecitabine Oxaliplatin Metastatic Gastric Gastroesophageal Cancer .</brief_title>
	<detailed_description>This single arm , open-label , multicentre , phase II trial patient metastatic gastric GEJ adenocarcinoma treat combination irinotecan , capecitabine , oxaliplatin ( IXO ) .Patients receive combination irinotecan , capecitabine , oxaliplatin recommend phase II dose sequence determine complete phase I trial . Patients treat study disease progression , overwhelming toxicity , consent withdrawal .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>histologically document gastric GEJ adenocarcinoma previously treat palliative systemic therapy . Metastatic disease base presence clinically and/or radiologically document measurable disease base RECIST . ECOG performance status 0,1 2 . Age ≥ 18 year Life expectancy least 3 month base discretion treat oncologist . Adequate hematologic , hepatic , renal function . Patients receive prior chemotherapy radiation deliver part initial curative therapy ( i.e . neoadjuvant adjuvant chemotherapy administer alone and/or concurrently deliver radiation and/or surgery ) permit long treatment complete least 6 month prior study start date . Patients may receive prior palliative radiotherapy ( unless radiation curative therapy pelvis ≥25 % bone marrow store ) radiation ≥ 4 week study entry patient must recover toxic effect treatment . Patients may receive prior surgery surgery ≥ 4 week study entry patient must recover toxic effect treatment . Patients must ability read , understand , sign informed consent must willing comply study treatment followup . Patients receive palliative chemotherapy metastatic gastric GEJ tumor . Prior treatment &gt; 6 cycle traditional alkylating agentbased chemotherapy , &gt; 2 cycle carboplatinbased chemotherapy , prior treatment irinotecan oxaliplatin chemotherapy , concurrent treatment experimental drug anticancer therapy . Curative radiation treatment pelvis radiation therapy ≥ 25 % bone marrow store . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , short gut syndrome , history bowel obstruction due peritoneal metastasis . Previous concurrent malignancy , exclude curatively treat situ carcinoma cervix nonmelanoma skin cancer , unless least 5 year elapse since last treatment patient consider cured . Any serious medical condition within 6 month prior study entry myocardial infarction , uncontrolled congestive heart failure , unstable angina , active cardiomyopathy , unstable ventricular arrhythmia , cerebrovascular disease , uncontrolled hypertension , uncontrolled diabetes , uncontrolled psychiatric disorder , serious infection , active peptic ulcer disease , medical condition ... .. Gilbert 's disease Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . Preexisting neuropathy ≥ grade 2 cause . Patients unstable metastasis central nervous system exclude . Patients treat brain metastasis steroid , anticonvulsant , document stability lesion least 3 month may eligible . A CT scan MRI NOT require rule brain metastasis unless clinical suspicion CNS involvement . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>irinotecan</keyword>
	<keyword>capecitabine</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>health-related quality life</keyword>
	<keyword>gastroesophageal ( GE ) junction adenocarcinoma</keyword>
</DOC>